Pediatric-Inspired Regimens in Adolescent and Young Adult ALL: Optimizing Asparaginase Therapy and Managing Adverse Events in Clinical Practice

Dr. Lewis Silverman from Columbia University Irving Medical Center and Dr. Emily Curran from the University of Cincinnati discuss pediatric-inspired asparaginase-based regimens for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), with a focus on the 2026 ASH guidelines for frontline ALL management in AYAs and the comprehensive expert consensus published in Haematologica on asparaginase adverse event management. The discussion addresses why pediatric-inspired regimens represent the standard of care for AYA ALL, barriers to real-world adoption including regimen complexity and asparaginase hesitancy, and the key adverse events that drive unnecessary discontinuation: hepatotoxicity, thrombosis, pancreatitis, and hypersensitivity. Therapeutic drug monitoring including asparaginase enzyme activity measurement, dose capping and empiric dose reduction strategies, pegaspargase premedication, and the critical distinction between true hypersensitivity and silent inactivation are discussed in depth. Experts describe practical management and the importance of managing through adverse events rather than discontinuing effective therapy.